NCT06064006View on ClinicalTrials.gov

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

November 27, 2024

Study Completion Date

November 27, 2024

Conditions
ObesityOverweight
Interventions
DRUG

NNC0487-0111

NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.

DRUG

Placebo (NNC0487-0111)

Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.

Trial Locations (2)

78209

ICON Early Phase Services, LLC, San Antonio

Novo Nordisk INvestigational Site, San Antonio

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY